CN101513442A - Capsule for treating diabetes - Google Patents
Capsule for treating diabetes Download PDFInfo
- Publication number
- CN101513442A CN101513442A CNA2009100199226A CN200910019922A CN101513442A CN 101513442 A CN101513442 A CN 101513442A CN A2009100199226 A CNA2009100199226 A CN A2009100199226A CN 200910019922 A CN200910019922 A CN 200910019922A CN 101513442 A CN101513442 A CN 101513442A
- Authority
- CN
- China
- Prior art keywords
- taurine
- capsule
- ganoderma
- zinc citrate
- insulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 30
- 239000002775 capsule Substances 0.000 title claims abstract description 19
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 74
- 229960003080 taurine Drugs 0.000 claims abstract description 37
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 claims abstract description 18
- 229940068475 zinc citrate Drugs 0.000 claims abstract description 18
- 235000006076 zinc citrate Nutrition 0.000 claims abstract description 18
- 239000011746 zinc citrate Substances 0.000 claims abstract description 18
- 241000222336 Ganoderma Species 0.000 claims abstract description 17
- 239000002994 raw material Substances 0.000 claims abstract description 11
- 235000012054 meals Nutrition 0.000 claims abstract description 7
- 239000000843 powder Substances 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 7
- 230000003203 everyday effect Effects 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 239000008280 blood Substances 0.000 abstract description 17
- 210000004369 blood Anatomy 0.000 abstract description 17
- 230000006870 function Effects 0.000 abstract description 7
- 210000004027 cell Anatomy 0.000 abstract description 5
- 230000006378 damage Effects 0.000 abstract description 4
- 230000001105 regulatory effect Effects 0.000 abstract description 4
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 3
- 206010020772 Hypertension Diseases 0.000 abstract description 3
- 206010022489 Insulin Resistance Diseases 0.000 abstract description 3
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 3
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 3
- 230000036737 immune function Effects 0.000 abstract description 3
- 208000017169 kidney disease Diseases 0.000 abstract description 3
- 230000008439 repair process Effects 0.000 abstract description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 2
- 210000002865 immune cell Anatomy 0.000 abstract description 2
- 210000000987 immune system Anatomy 0.000 abstract description 2
- 230000003914 insulin secretion Effects 0.000 abstract description 2
- 210000004153 islets of langerhan Anatomy 0.000 abstract description 2
- 210000000496 pancreas Anatomy 0.000 abstract description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 2
- 235000009811 Momordica charantia Nutrition 0.000 abstract 2
- 244000078912 Trichosanthes cucumerina Species 0.000 abstract 2
- 235000008322 Trichosanthes cucumerina Nutrition 0.000 abstract 2
- 240000008397 Ganoderma lucidum Species 0.000 abstract 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 238000010298 pulverizing process Methods 0.000 abstract 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 42
- 102000004877 Insulin Human genes 0.000 description 21
- 108090001061 Insulin Proteins 0.000 description 21
- 229940125396 insulin Drugs 0.000 description 21
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 16
- 239000011701 zinc Substances 0.000 description 16
- 229910052725 zinc Inorganic materials 0.000 description 16
- 230000000694 effects Effects 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 201000001421 hyperglycemia Diseases 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 101000852815 Homo sapiens Insulin receptor Proteins 0.000 description 4
- 102100036721 Insulin receptor Human genes 0.000 description 4
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 206010007749 Cataract diabetic Diseases 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000023852 carbohydrate metabolic process Effects 0.000 description 3
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 3
- 201000007025 diabetic cataract Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 206010012655 Diabetic complications Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 102000003746 Insulin Receptor Human genes 0.000 description 2
- 108010001127 Insulin Receptor Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000000695 crystalline len Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 230000002608 insulinlike Effects 0.000 description 2
- 210000001542 lens epithelial cell Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 1
- 241000219112 Cucumis Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 206010024214 Lenticular opacities Diseases 0.000 description 1
- 241000218984 Momordica Species 0.000 description 1
- 206010038491 Renal papillary necrosis Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 206010048259 Zinc deficiency Diseases 0.000 description 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000004392 development of vision Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000014101 glucose homeostasis Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000008558 metabolic pathway by substance Effects 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000004203 pancreatic function Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
A capsule for treating diabetes, it uses taurine, Ganoderma lucidum, bitter gourd, zinc citrate as raw materials, characterized by that it is a capsule made of raw materials of the following weight proportion; 20-50 g of taurine, 500-2000 g of lucid ganoderma, 1000-2000 g of bitter gourd and 8-15 g of zinc citrate. Extracting Ganoderma and fructus Momordicae Charantiae, concentrating, pulverizing into powder, mixing with taurine and zinc citrate, and making into capsule, wherein each capsule is 0.45g, and is taken 2 capsules 3 times a day before or after meal for 2 months as a treatment course. The invention has the advantages that the blood sugar is biologically regulated; can rapidly eliminate insulin resistance of patients, increase insulin sensitivity of patients, repair damaged islet cells, recover insulin secretion function of pancreas, enable blood sugar to be absorbed and utilized by organism tissue cells again, can act on an organism immune system while regulating blood sugar, activate immune cells, comprehensively enhance immune functions of various organ tissues and systems, and reduce complications such as hypertension, hyperlipidemia, cardiovascular and cerebrovascular diseases, nephropathy, intelligence injury and the like.
Description
Technical field
The present invention relates to a kind of Chinese medicine preparation, specifically a kind of capsule that is used for the treatment of diabetes..
Background technology
At present, known diabetes are one of diseases that have a strong impact on human health.Without the diabetic of suitably treatment easily take place to infect and wound healing bad.Chronic complication comprises the generation microvascular abnormality, causes retinopathy and nephropathy, peripheral nervous disease and other delayed ischemic neurological deficits, and infectious disease takes place.Very easily concurrent in addition cardiovascular and cerebrovascular disease, and these intercurrent diseases can become the main cause that threatens diabetic life.In recent years, along with the Chinese society economic development, living standards of the people improve, and the onset diabetes rate rises year by year.China diabetes patient has 3000-4000 ten thousand at least at present, wherein is non-insulin-depending type (II type) diabetes more than 90%.In addition, also having 3,000 ten thousand people is diabetes Susceptible population.Therefore, develop the novel medicine or the health food that are fit to the diabetics use and seem very important.
Summary of the invention
Technical problem to be solved by this invention is the deficiency that has now on the treatment technology in order to overcome, and a kind of capsule that is used for the treatment of diabetes is provided, and not only therapeutic effect is good, and cheap, taking convenience.
The technical solution adopted for the present invention to solve the technical problems is: a kind of capsule that is used for the treatment of diabetes, and it adopts taurine, Ganoderma, Fructus Momordicae charantiae, zinc citrate is raw material, it is characterized in that it is the capsule of being made by the following weight proportion raw material;
Taurine 20-50g Ganoderma 500-2000g Fructus Momordicae charantiae 1000-2000g zinc citrate 8-15g Ganoderma, Fructus Momordicae charantiae are encapsulated with taurine, zinc citrate mix homogeneously through extracting after concentrating powder process; every 0.45g, every day 3 times, each 2; ante cibum or one after each meal, 2 months is a course of treatment.
The preparation capsular optimization formula of the present invention (consumption is a weight portion) is;
Taurine 25-45g Ganoderma 600-1900g Fructus Momordicae charantiae 900-1900g zinc citrate 10-13g Ganoderma, Fructus Momordicae charantiae are encapsulated with taurine, zinc citrate mix homogeneously through extracting after concentrating powder process; every 0.45g, every day 3 times, each 2; ante cibum or one after each meal, 2 months is a course of treatment.
The invention has the beneficial effects as follows one; Biological modulated blood glucose; This product can be eliminated patient's insulin resistant rapidly, increases the sensitivity of patient self insulin, repairs impaired islet cells, and the function of recovery pancreatic secretion insulin can be absorbed blood glucose again and utilized blood sugar regulation by the body tissue cell.Two; Enhancing immunity is in blood sugar regulation comprehensively, also can act on body immune system, activating immune cell strengthens the immunologic function of each organ-tissue and system comprehensively, reduces complication such as hypertension, hyperlipidemia, cardiovascular and cerebrovascular disease, nephropathy, intellectual damage.
Compound basis; Taurine has biochemical function widely in vivo.Discovered in recent years, taurine has significant curative effect to preventing and treating diabetes, not only can reduce the intravital hyperglycemia level of diabetics and laboratory animal, also can improve diabetic symptom.Discover that taurine has the Insulin-Like effect, it can promote insulin target cell ingestion of glucose; accelerate it and penetrate speed; and promote intracellular carbohydrate metabolism and glycogen synthetic, this discharges under the situations such as deficiency or insulin resistant at insulin, has important compensatory meaning.Discoveries such as Wu Zhenguo, the glycometabolic regulating action of taurine pair cell may realize that it mainly relies on the interaction with insulin receptor protein, rather than directly combines with Insulin receptor INSR by mechanism behind the receptor.But taurine facedown beta Cell of islet damage, keep its structural intergrity and promotion is damaged the cytothesis double protection.Taurine also has the effect of control diabetic complication, especially can obviously alleviate diabetes rat kidney, the infringement of visual system 26S Proteasome Structure and Function.Taurine can suppress the streptozotocin diabetic cataract to be taken place; this effect not only forms relevant with its early stage blocking-up hyperglycemia; also may with the taurine that wanes in its compensation diabetic cataract crystalline lens, the protection lens epithelial cells avoids oxidative damage and suppresses lens epithelial cell apoptosis relevant.In addition, taurine can make the interior SOD vigor of crystalline lens significantly raise, and MDA content obviously reduces, and cataractous time of origin is postponed, and the lenticular opacity degree is obviously improved, thus the generation of prevention and alleviation diabetic cataract.Especially in recent years both at home and abroad taurine is promoted development of vision system, improves visual performance and done big quantity research, find that also taurine can effectively alleviate diabetic renal papillary necrosis simultaneously.
In a word, taurine not only can act on Insulin receptor INSR, performance Insulin-Like effect, and the insulin of can also working in coordination with or superpose participates in keeping body glucose homeostasis to glycometabolic regulating and controlling effect; As the endogenous cell protective agent; taurine can also effectively reduce hyperglycemia level in the diabetics body; the endocrine function of protection beta Cell of islet; suppress interior environment disorder of a series of histiocytes and structural damage that hyperglycemia state causes, diabetes and complication thereof are had obvious cytoprotection.In addition; because taurine is a small-molecule substance; no antigen and toxic and side effects; safe dose is big; no drug dependence and drug resistance are used in oral easy absorption repeatedly, and little to normal blood sugar level influence; thereby there is the people to think that taurine may be a kind of important anti-diabetic material in the body, is having broad prospects aspect treating diabetes and the clinical practice.
Polysaccharide has wide biological activity, with to keep biological function closely related.Discover that in a large number polysaccharide has antitumor, blood sugar lowering, raise immunity and the anti-ageing effect of waiting for a long time, so polysaccharide becomes one of important directions of current new drug development gradually.Discover that polysaccharide can not only insulin secretion accelerating, can also increase Insulin receptor INSR or improve its affinity, improves its sensitivity to insulin, reduce the blood sugar level of normal and experimental diabetic animal.In addition, ganoderan is the activity of scalable carbohydrate metabolism enzyme also, suppresses glyconeogenesis, promotes the utilization of glucose, improves carbohydrate metabolism disturbance and insulin resistant.
Fructus Momordicae charantiae is a Cucurbitaceae Momordica plant, and meat is tender, and bitter in the mouth cold in nature is rich in multiple nutritional components, especially ascorbic content be in various melon first of.Fructus Momordicae charantiae extract has the various biological activity, as blood sugar lowering, antitumor, inhibition HIV (human immunodeficiency virus) etc.There is multiple blood sugar reducing component in the Fructus Momordicae charantiae, it is generally acknowledged at present to comprise sterioside, saponin, brain glycosides, alkaloid and peptide matters.Pharmacological testing is found, contained Fructus Momordicae charantiae saponin in the Fructus Momordicae charantiae, similar ILA is arranged, can be rated as glucokinin, very obvious functions of blood sugar effect is arranged, energy safety, steady blood sugar lowering, and can also improve pancreatic function, and repair the β cell, the human insulin cytoactive is strengthened, the effect that have blood lipid regulation simultaneously, brings high blood pressure down improves significantly to complication.Someone tests, and with Fructus Momordicae charantiae saponin preparation oral treatment shape of the mouth as one speaks diabetes, total effective rate can reach 78.3%.
Zinc is one of trace element of wanting of body weight for humans, since confirming to contain zinc in the insulin crystal thirties in last century, about the research of zinc and insulin, diabetes relation just becomes the research focus.In recent years along with the onset diabetes rate raises gradually, progressively be familiar with in the intravital metabolism of diabetics, problems such as effect in insulin metabolism and function by people about zinc.
Insulin is a kind of proteohormone of pancreatic beta-emiocytosis.Pancreas is comparatively responsive to the zinc metabolism, and beta cell has very strong accumulation, shifts the ability of zinc.Zinc participates in the synthetic and secretion of insulin, and can influence the Insulin receptor INSR effect in many aspects.Zinc promotes insulin and receptors bind, activated zinc can combine with agonist, receptor or material that some are unknown, promote receptor clustering and phosphorylation, increase the affinity of insulin-receptor, reduce insulin and decompose and the receptor recirculation, and behind receptor or receptor the horizontal adjustment insulin action.Zinc has ILA in substance metabolism.If the zinc abundance, body reduces the requirement of insulin, and zinc can be kept insulin active.Zinc, is kept disulfide bond and is in reducing condition in the synthetic and storage process at insulin, avoids being damaged owing to the disulfide bond oxidation makes insulin.And zinc deficiency can be induced generation insulin resistance or the reaction of diabetes sample.
In addition; a large amount of researchs all confirm; taurine, ganoderan and zinc can both effectively promote immune development, enhancing body specificity and non-specific immunity, the secretion of stimulating cytokine and antibody, promote lymphopoiesis to transform and macrophage engulf sterilizing ability.And concerning diabetic,, cause infectious disease to become later stage severe complications comparatively because hyperglycemia and the resistance in later stage reduce.Therefore, strengthen the diabetics immunologic function no less important that seems.
In sum, we have following characteristics:
1. be main functional component with taurine, ganoderan and zinc, can bring into play its collaborative hypoglycemic activity;
2. we are when considering function of blood sugar reduction; also preventing or alleviating diabetic complication as a main target; as being its major complications at diabetics later stage infectious disease and visual impairment; selected for use existing clear and definite effect of lowering blood sugar, again can raise immunity taurine, ganoderan and zinc be main functional component, taurine and zinc can also improve the infringement of diabetes visual performance simultaneously.
3. Fructus Momordicae charantiae is cheap and good-quality medicinal plants, wherein contains blood-sugar decreasing active, can bring into play its collaborative hypoglycemic activity with mentioned component equally;
4. raw material sources facility, processing technique are comparatively ripe, and especially Fructus Momordicae charantiae extract adopts the cryoconcentration technology, can effectively keep blood-sugar decreasing active.
The specific embodiment
The invention will be further described below in conjunction with embodiment;
Embodiment 1: a kind of capsule that is used for the treatment of diabetes, and it adopts taurine, Ganoderma, Fructus Momordicae charantiae, zinc citrate is raw material, it is characterized in that it is the capsule of being made by the following weight proportion raw material;
Taurine 20-50g Ganoderma 500-2000g Fructus Momordicae charantiae 1000-2000g zinc citrate 8-15g Ganoderma, Fructus Momordicae charantiae are encapsulated with taurine, zinc citrate mix homogeneously through extracting after concentrating powder process; every 0.45g, every day 3 times, each 2; ante cibum or one after each meal, 2 months is a course of treatment.
Embodiment 2: a kind of capsule that is used for the treatment of diabetes is characterized in that it is the capsule of being made by the following weight proportion raw material;
Taurine 25-45g Ganoderma 600-1900g Fructus Momordicae charantiae 900-1900g zinc citrate 10-13g Ganoderma, Fructus Momordicae charantiae are encapsulated with taurine, zinc citrate mix homogeneously through extracting after concentrating powder process; every 0.45g, every day 3 times, each 2; ante cibum or one after each meal, 2 months is a course of treatment.
Claims (2)
1. capsule that is used for the treatment of diabetes, it adopts taurine, Ganoderma, Fructus Momordicae charantiae, zinc citrate is raw material, it is characterized in that it is the capsule of being made by the following weight proportion raw material;
Taurine 20-50g Ganoderma 500-2000g Fructus Momordicae charantiae 1000-2000g zinc citrate 8-15g Ganoderma, Fructus Momordicae charantiae are encapsulated with taurine, zinc citrate mix homogeneously through extracting after concentrating powder process; every 0.45g, every day 3 times, each 2; ante cibum or one after each meal, 2 months is a course of treatment.
2. the described a kind of capsule that is used for the treatment of diabetes of root a tree name claim 1 is characterized in that it is the capsule of being made by the following weight proportion raw material;
Taurine 25-45g Ganoderma 600-1900g Fructus Momordicae charantiae 900-1900g zinc citrate 10-13g Ganoderma, Fructus Momordicae charantiae are encapsulated with taurine, zinc citrate mix homogeneously through extracting after concentrating powder process; every 0.45g, every day 3 times, each 2; ante cibum or one after each meal, 2 months is a course of treatment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2009100199226A CN101513442A (en) | 2009-03-15 | 2009-03-15 | Capsule for treating diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2009100199226A CN101513442A (en) | 2009-03-15 | 2009-03-15 | Capsule for treating diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101513442A true CN101513442A (en) | 2009-08-26 |
Family
ID=41038164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2009100199226A Pending CN101513442A (en) | 2009-03-15 | 2009-03-15 | Capsule for treating diabetes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101513442A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2564013C2 (en) * | 2013-10-08 | 2015-09-27 | Закрытое акционерное общество "Алтайвитамины" | Dietary supplement for preventing heart rhythm disorder |
| RU2564013C9 (en) * | 2013-10-08 | 2016-02-10 | Закрытое акционерное общество "Алтайвитамины" | Agent for preventing heart rhythm disorder |
| CN112704693A (en) * | 2020-12-31 | 2021-04-27 | 吴杰 | A Chinese medicinal extract composition for preventing and treating diabetes |
-
2009
- 2009-03-15 CN CNA2009100199226A patent/CN101513442A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2564013C2 (en) * | 2013-10-08 | 2015-09-27 | Закрытое акционерное общество "Алтайвитамины" | Dietary supplement for preventing heart rhythm disorder |
| RU2564013C9 (en) * | 2013-10-08 | 2016-02-10 | Закрытое акционерное общество "Алтайвитамины" | Agent for preventing heart rhythm disorder |
| CN112704693A (en) * | 2020-12-31 | 2021-04-27 | 吴杰 | A Chinese medicinal extract composition for preventing and treating diabetes |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103734751B (en) | A kind of composite dietary and method for making thereof | |
| CN102488281A (en) | Novel pure plant composite concentrated drinking liquid with blood sugar reducing effect, and preparation method thereof | |
| CN107080250A (en) | A kind of composition of auxiliary hyperglycemic, beverage and preparation method thereof | |
| CN102697035A (en) | Cordyceps anti-aging pellet | |
| CN102526479A (en) | Health-care medicine formula with functions of enhancing immunity and lowering blood sugar | |
| CN101450095A (en) | Medicine composition with blood-sugar reduction function and preparation method thereof | |
| CN104337871A (en) | Blood sugar reducing capsule | |
| CN105661547A (en) | Probiotics and Bombyx mori compounded diabetic patient nutritional supplement | |
| CN1329049C (en) | Blood sugar- and blood pressure-lowering medicine | |
| CN101450101A (en) | Medicine composition with blood-sugar reduction function and preparation method thereof | |
| CN102068475B (en) | Application and blood-sugar lowering effective part of trapa acornis nakano shell as well as extraction method of blood-sugar lowering effective part | |
| CN110693029A (en) | Mulberry leaf and bitter gourd functional food capable of reducing blood sugar | |
| CN102178718B (en) | Preparation used for treating diabetes mellitus and preventively treating heart cerebrovascular disease | |
| CN104644734A (en) | Drug for treating type II diabetes and complications thereof | |
| CN101513442A (en) | Capsule for treating diabetes | |
| CN105031248B (en) | It is a kind of containing selenium worm grass can auxiliary hyperglycemic health care product | |
| CN101433597A (en) | Chinese medicinal composition with function for reducing blood sugar and preparation method thereof | |
| CN101564511B (en) | Natural protein product for treating diabetes and manufacture method | |
| CN106798854A (en) | Emblic mulberry leaf piece and preparation method thereof | |
| CN101491668B (en) | Composition with blood-sugar reducing function and preparation method thereof | |
| CN101450174A (en) | Medicine composition with blood-sugar reduction function and preparation method thereof | |
| CN104888023A (en) | Traditional Chinese medicine preparation for decreasing blood sugar | |
| CN101053598B (en) | Medicinal composition for treating cardio-cerebralvascular diseases and diabetes | |
| CN104413195A (en) | Eichhornia-crassipes blood-sugar-reducing tea and preparation method thereof | |
| CN103721074B (en) | Pharmaceutical composition and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20090826 |